Paul N. Durrington

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington et al. · The Lancet · 2004 · 3.8K citations

Metabolic Syndrome, Primary Prevention, Diabetes Management +8

LMNA, encoding lamin A/C, is mutated in partial lipodystrophy

Sue Shackleton, David J. Lloyd, Stephen N.J. Jackson et al. · Nature Genetics · 2000 · 695 citations

Cell Biology, Lamin A/c, Molecular Biology +1

Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus

Michael I. Mackness, D. W. S. Harty, Deepak Bhatnagar et al. · Atherosclerosis · 1991 · 491 citations

Metabolic Syndrome, Serum Paraoxonase Activity, Medicine +8

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

Philip J. Barter, Christie M. Ballantyne, Rafael Carmena et al. · Journal of Internal Medicine · 2006 · 470 citations · Full text

Paraoxonase Status in Coronary Heart Disease

Bharti Mackness, Gershan K. Davies, Wajdi Turkie et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2001 · 434 citations

Lipid Peroxidation, Hyperlipidemia, Oxidative Stress +17